Available Technologies

Details

Project TitlePredictive Biomarkers for TAS102 Efficacy in Colorectal Cancer Patients
Track Code2016-113
Short Description
Abstract
 
Tagscolorectal cancer, TAS102 therapy, clinical outcome marker, oncology, biomarkers
 
Posted DateMar 10, 2017 12:55 PM

Market Opportunity

TAS102 is an oral combination of trifluridine (FTD), a nucleoside analog, and tipiracil hydrochloride, a thymidine phosphorylase inhibitor. Colorectal cancer patients harboring certain genotypes are likely to experience more desirable clinical outcomes when treated with a therapy comprising TAS102 as compared to those not having the genotype.

USC Solution

USC researchers have discovered that refractory metastatic colorectal cancer patients harboring certain variants of DNA repair-related genes are likely to experience more desirable clinical outcomes when treated with a therapy comprising TAS102. Desirable clinical outcomes include higher likelihood to respond to the therapy, longer progression-free survival (PFS), longer overall survival (OS), and milder or lower likelihood of adverse effects.

Value Proposition

  • Simple genotyping test
  • Ability to select patients more likely to respond to TAS102 therapy
  • More desirable clinical outcomes

Applications

  • Colorectal cancer treatment
  • Selection of patients for TAS-102 therapy

Stage of Development

  • Multivariate analysis performed in clinical samples

Intellectual Property

Contact Information

Camilo Ansarah-Sobrinho, Licensing Associate, Life Sciences

USC Stevens Center for Innovation

(213) 821-6071

ansarahs@usc.edu

Files

File Name Description
NCD 2016-113 - Predictive Biomarkers for TAS102 Efficacy in Colorectal Cancer Patients.pdf None Download